All In Biotech

NDA 022518 · Organon LLC

Dulera

Formoterol Fumarate, Mometasone Furoate · Inhalation

Last checked: Nov 20, 2026Latest source record: Jun 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Jun 22, 2010

Approved uses

4

Original approval plus efficacy supplements

Registered trials

514

215 Phase 3, 21 recruiting

FAERS reports

16,226

4,892 serious, 443 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 10, 2026.

DULERA is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist (LABA) indicated for: Treatment of asthma in patients 5 years of age and older. ( 1.1 ) Important Limitation of Use: Not indicated for the relief of acute bronchospasm. ( 1.1 ) 1.1 Treatment of Asthma DULERA is indicated for the twice-daily treatment of asthma in patients 5 years of age and older. DULERA should be used for patients not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta 2 -adrenergic agonist (LABA). Important Limitation of Use: DULERA is NOT indicated for the relief of acute bronchospasm.

Mechanism: DULERA: DULERA contains both mometasone furoate and formoterol fumarate; therefore, the mechanisms of actions described below for the individual components apply to DULERA. These drugs represent two different classes of medications (a synthetic corticosteroid and a selective long-acting beta 2 -adrenergic receptor agonist) that have different effects on clinical, physiological, and inflammatory indices of asthma. Mometasone furoate : Mometasone furoate is a corticosteroid demonstrating potent anti-inflammatory activity. The precise mechanism of corticosteroid action on asthma is not known....

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • DULERA · FORMOTEROL FUMARATE 0.005MG/INH; MOMETASONE FUROATE 0.2MG/INH · AEROSOL, METERED, INHALATION · Prescription
  • DULERA · FORMOTEROL FUMARATE 0.005MG/INH; MOMETASONE FUROATE 0.05MG/INH · AEROSOL, METERED, INHALATION · Prescription
  • DULERA · FORMOTEROL FUMARATE 0.005MG/INH; MOMETASONE FUROATE 0.1MG/INH · AEROSOL, METERED, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Formoterol" as an intervention, any sponsor and status, largest first.

All 514 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product quality issue3,321
  • no adverse event3,122
  • drug dose omission2,135
  • dyspnoea1,794
  • poor quality device used1,556
  • device malfunction1,238
  • cough913
  • drug ineffective886
  • asthma858
  • product dose omission issue769
  • fatigue658
  • headache627

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20101
201112
2012512
20131,067
20141,447
20151,603
20161,892
20171,606
20181,400
20191,294
20201,209
2021951
2022828
2023446
2024510
2025486
2026962

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Dulera (Mometasone/Formoterol)

2024 spending

$162M

Beneficiaries

105,783

369,910 claims

Per beneficiary

$1,532

$26.10 per unit

View as table
YearSpending
2020$0
2021$13,587,323
2022$100,804,525
2023$116,998,631
2024$162,082,133

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,013 on PubMed

Sponsor: Organon LLC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.